Study of Hyperbaric Oxygen Therapy Effects on Radiation Cystitis Symptoms and Urine Inflammation Markers in Adults

What this Trial Is About

This research aims to understand chronic radiation cystitis and how hyperbaric oxygen therapy affects patient-reported outcomes and urine inflammatory biomarkers. The study is observational and includes participants with radiation cystitis as well as controls without radiation exposure to compare differences. It focuses on assessing urine markers related to inflammation and oxidative stress over time. Participants are divided into four groups those with radiation cystitis undergoing hyperbaric oxygen therapy, those receiving the therapy without prior pelvic radiation, healthy controls without radiation or therapy history, and those with radiation cystitis who choose not to undergo the therapy. Hyperbaric oxygen therapy involves placing patients in pressurized chambers with 100% oxygen at specific pressures for about 80 to 90 minutes daily, up to 60 sessions. During the study, participants provide urine, blood, and tissue samples to measure markers like urinary 8-Hydroxy-2-deoxyguanosine, TNF-alpha, IL-6, and VEGF from baseline up to 12 months after therapy. Researchers also track hematuria events, urinary distress scores, and quality of life assessments. Study involvement lasts up to a year with regular monitoring to observe changes related to therapy and condition progression.

Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers